ATM Gene Mutations and Radiotherapy Complications in Breast Cancer
Author Information
Author(s): M Shayeghi, S Seal, J Regan, N Collins, R Barfoot, N Rahman, A Ashton, M Moohan, R Wooster, R Owen, JM Bliss, MR Stratton, J Yamold
Primary Institution: Institute of Cancer Research
Hypothesis
Does heterozygosity for mutations in the ATM gene contribute to radiotherapy complications in breast cancer patients?
Conclusion
ATM gene defects are not the major cause of radiotherapy complications in women with breast cancer.
Supporting Evidence
- One out of 41 cases showed a mutation predicted to generate a truncated protein.
- No truncating mutations were detected in the control subjects.
- The estimated percentage of AT heterozygous patients in radiosensitive cases was 2.4%.
Takeaway
Some women have bad reactions to radiation treatment for breast cancer, but having a certain gene mutation doesn't seem to be the main reason.
Methodology
The study screened 41 breast cancer patients with adverse reactions and 39 control subjects for mutations in the ATM gene.
Limitations
The study may have missed some mutations due to the screening technique used.
Participant Demographics
Participants included 41 breast cancer patients with marked changes after radiotherapy and 39 control subjects without detectable reactions.
Statistical Information
Confidence Interval
95% (0.1-12.9%)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website